RESOLVING THE LEDGER
This is one outlet's own report from The Motley Fool — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 2 sources
The VanEck Pharmaceutical ETF (NASDAQ:PPH) provides concentrated exposure to drugmakers, while the State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers a broader, lower-cost gateway to the entire healthcare sector.
The healthcare sector remains a foundational component of many diversified portfolios, offering a unique combination of defensive stability and long-term growth potential driven by medical innovation. When navigating this space, investors often weigh the benefits of broad diversification against the potential for targeted returns in specialized niches like pharmaceuticals. This comparison explores the fundamental trade-offs between a diversified industry giant and a more concentrated drugmaker strategy. By examining the differences in cost structures, historical total returns, and underlying portfolio concentrations, investors can better understand which vehicle may be appropriate for their specific financial goals, risk tolerance, and income requirements in a changing market.
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the close of trading on July 23.
Continue reading
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.